PHOXILLUMBK4/2.5 (Baxter Healthcare Corporation)
Welcome to the PulseAid listing for the PHOXILLUM drug offered from Baxter Healthcare Corporation. This Blood Coagulation Factor [EPC],Increased Coagulation Factor Activity [PE],Calcium [Chemical/Ingredient],Cations, Divalent [Chemical/Ingredient],Calculi Dissolution Agent [EPC],Magnesium Ion Exchange Activity [MoA],Osmotic Laxative [EPC],Osmotic Activity [MoA],Inhibition Small Intestine Fluid/Electrolyte Absorption [PE],Increased Large Intestinal Motility [PE],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Baxter Healthcare Corporation |
NON-PROPRIETARY NAME: | calcium chloride, magnesium chloride, sodium chloride, potassium chloride, sodium phosphate dibasic dihydrate, and sodium bicarbonate |
SUBSTANCE NAME: | CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC DIHYDRATE; SODIUM BICARBONATE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Blood Coagulation Factor [EPC],Increased Coagulation Factor Activity [PE],Calcium [Chemical/Ingredient],Cations, Divalent [Chemical/Ingredient],Calculi Dissolution Agent [EPC],Magnesium Ion Exchange Activity [MoA],Osmotic Laxative [EPC],Osmotic Activity [MoA],Inhibition Small Intestine Fluid/Electrolyte Absorption [PE],Increased Large Intestinal Motility [PE],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | SOLUTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2015-01-13 |
END MARKETING DATE: | 0000-00-00 |
PHOXILLUM BK4/2.5 HUMAN PRESCRIPTION DRUG Details:
Item Description | PHOXILLUM BK4/2.5 from Baxter Healthcare Corporation |
LABELER NAME: | Baxter Healthcare Corporation |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | .184; .153; 6.019; .298; .178; 2.688(g/L; g/L; g/L; g/L; g/L; g/L) |
START MARKETING DATE: | 2015-01-13 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 24571-116_de471206-dcf9-4219-8282-1d6e48141f93 |
PRODUCT NDC: | 24571-116 |
APPLICATION NUMBER: | NDA207026 |
Other CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC DIHYDRATE; SODIUM BICARBONATE Pharmaceutical Manufacturers / Labelers: